TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02076945

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US-guided sciatic block at the popliteal crease (30 mL1:1 mixture of lidocaine 1% and bupivacaine 0.5%)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US-guided sciatic block at the popliteal crease (30 mL1:1 mixture of lidocaine 1% and bupivacaine 0.5%)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-guided sciatic block at the popliteal crease (30 mL1:1 mixture of lidocaine 1% and bupivacaine 0.5%)
Study: NCT01159093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Decision Support
Description: Family-focused intervention includes informational vaccine reminder telephone calls prompted by an electronic health record.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Decision Support
Description: Family-focused intervention includes informational vaccine reminder telephone calls prompted by an electronic health record.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Decision Support
Description: Clinician-focused intervention includes an electronic health record-based decision support mechanism including reminders, education, audit and feedback on vaccination success.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Decision Support
Description: Clinician-focused intervention includes an electronic health record-based decision support mechanism including reminders, education, audit and feedback on vaccination success.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Decision Support and Clinician Decision Support
Description: This will be a combination of the family-focused decision support (telephone reminder calls) and clinician-focused decision support (clinical alerts).

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Usual care
Study: NCT04236271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: connected objects
Description: a combination of connected devices for measuring physiological parameters and for clinical self-assessment by the patient, for early postoperative coronary bypass surgeries.
Study: NCT05725122

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy
Description: Extracorporeal shock wave lithotripsy will given to the patients
Study: NCT02318407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 403
Description: AMG 403 for the treatment of subjects with osteoarthritis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: contains no active drug
Study: NCT04185311

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study: NCT03341923

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A multifocal contact lenses
Description: Hydrogel multifocal contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A multifocal contact lenses
Description: Hydrogel multifocal contact lenses for daily disposable wear
Study: NCT02930369

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ILM peeling surgery
Description: 4PD or 2PD diameter of ILM peeling in surgery was given to patients with idiopathic macular hole (IMH)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ILM peeling surgery
Description: 4PD or 2PD diameter of ILM peeling in surgery was given to patients with idiopathic macular hole (IMH)
Study: NCT05046678

Intervention type: DIAGNOSTIC_TEST
Intervention: Control
Description: probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium and nonsmokers if they had no previous history of smoking

Intervention type: DIAGNOSTIC_TEST
Intervention: Control
Description: probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium and nonsmokers if they had no previous history of smoking

Intervention type: DIAGNOSTIC_TEST
Intervention: Control
Description: probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium and nonsmokers if they had no previous history of smoking

Intervention type: DIAGNOSTIC_TEST
Intervention: Control
Description: probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium and nonsmokers if they had no previous history of smoking

Intervention type: DIAGNOSTIC_TEST
Intervention: Control
Description: probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium and nonsmokers if they had no previous history of smoking
Study: NCT01290185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of different catheters for continuous nerve block
Description: Placement different catheters adjacent to the femoral
Study: NCT05725122

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Lithotripsy combined with Tamsulosin Therapy.
Description: Extracorporeal Shock Wave Lithotripsy combined with Tamsulosin Therapy will be given to the patients
Study: NCT05850143

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Oral Dexamethasone a longer and potent corticosteroid with lesser sideffects and good compliance
Study: NCT01290185

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of different catheters for continuous nerve block
Description: Placement different catheters adjacent to the femoral
Study: NCT01765231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir prophylaxis
Description: Entecavir 0.5mg daily from day 1 of antitumor therapy to at least 6 months after completing antitumor therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Observation arm
Description: Entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation.
Study: NCT02191098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Interleukin 15 (IL-15) is a common γ-chain cytokine that is related to interleukin-2 (IL-2) and is a critical factor for the development, proliferation, and activation of effector natural killer (NK) and CD8+ memory T cells
Study: NCT05046678

Intervention type: DIAGNOSTIC_TEST
Intervention: Smokers with periodontally healthy
Description: probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium and smokers if they had smoked ≥10 cigarettes/day for ≥5 years
Study: NCT02768467

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue Matrix Graft Placement
Description: Subject will receive a covering for the wound post buccal mucosa removal.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No Stitches
Description: Subject will not receive stitches post buccal mucosa removal.
Study: NCT04065334

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High dose training
Description: 4 x 4 minutes of high intensity workload on treadmill and 4 repetitions x 4 sets of high intensity workload in hack squat

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low dose training
Description: 1 x 4 minutes of high intensity workload on treadmill and 2 repetitions x 4 sets of high intensity workload in hack squat
Study: NCT04111328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous sufentanil
Description: The PCA pumps contain sufentanil . And the pump is connected to participants intravenously .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous sufentanil
Description: The PCA pumps contain sufentanil. And the pump is connected to participants subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous hydromorphone
Description: The PCA pumps contain hydromorphone. And the pump is connected to participants intravenously .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous hydromorphone
Description: The PCA pumps contain hydromorphone. And the pump is connected to participants subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous sufentanil and dexmedetomidine
Description: The PCA pumps contain sufentanil and dexmedetomidine. And the pump is connected to participants intravenously .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous sufentanil and dexmedetomidine
Description: The PCA pumps contain sufentanil and dexmedetomidine. And the pump is connected to participants subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous hydromorphone and dexmedetomidine
Description: The PCA pumps contain hydromorphone and dexmedetomidine. And the pump is connected to participants intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous hydromorphone and dexmedetomidine
Description: The PCA pumps contain hydromorphone and dexmedetomidine. And the pump is connected to participants subcutaneously
Study: NCT01736215

Intervention type: DRUG
Intervention: Erythropoietin: Observational study
Description: This is an observational study. Participants receiving erythropoietin (dosage and regimen will comply with Thai Food and Drug Administration approval package insert) will be observed.
Study: NCT05850143

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Oral Multidose Prednisolone
Study: NCT05058534

Intervention type: DEVICE
Intervention: Multiline Neo®
Description: Multiperfusion neonatal system
Study: NCT04595916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyene phosphatidylcholine injection 930 mg QD
Description: Polyene phosphatidylcholine injection 930mg, diluted with 5% glucose solution 250ml, once a day, at least 2 weeks but no more than 4 weeks.
Study: NCT05046678

Intervention type: DIAGNOSTIC_TEST
Intervention: Smokers with periodontally healthy
Description: probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium and smokers if they had smoked ≥10 cigarettes/day for ≥5 years

Intervention type: DIAGNOSTIC_TEST
Intervention: Smokers with periodontally healthy
Description: probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium and smokers if they had smoked ≥10 cigarettes/day for ≥5 years

Intervention type: DIAGNOSTIC_TEST
Intervention: Smokers with periodontally healthy
Description: probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium and smokers if they had smoked ≥10 cigarettes/day for ≥5 years

Intervention type: DIAGNOSTIC_TEST
Intervention: Smokers with periodontally healthy
Description: probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium and smokers if they had smoked ≥10 cigarettes/day for ≥5 years
Study: NCT01173679

Intervention type: DRUG
Group type: OTHER
Intervention: dasatinib
Description: Taken orally once a day on days 1-14 of each 28-day cycle

Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab
Description: Given intravenously, 375 mg/m2 each cycle (dose split, given on Days 3+4 of cycle 1, variable after that).

Intervention type: DRUG
Group type: OTHER
Intervention: fludarabine
Description: Given intravenously, 25 mg/m2/day, for 3 doses per cycle (Days 3-5 in cycle 1, Days 1-3 after that)
Study: NCT00710944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASTRA TECH Implant System, OsseoSpeed™
Description: ASTRA TECH Implant System, OsseoSpeed™: Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASTRA TECH Implant System, OsseoSpeed™
Description: ASTRA TECH Implant System, OsseoSpeed™: Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm.
Study: NCT05046678

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-smokers with gingivitis
Description: without attachment and alveolar bone loss who had gingival inflammation, PD ≤ 3 mm and BOP \> 30% in the full mouth and nonsmokers if they had no previous history of smoking

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-smokers with gingivitis
Description: without attachment and alveolar bone loss who had gingival inflammation, PD ≤ 3 mm and BOP \> 30% in the full mouth and nonsmokers if they had no previous history of smoking

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-smokers with gingivitis
Description: without attachment and alveolar bone loss who had gingival inflammation, PD ≤ 3 mm and BOP \> 30% in the full mouth and nonsmokers if they had no previous history of smoking
Study: NCT00710944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASTRA TECH Implant System, OsseoSpeed™
Description: ASTRA TECH Implant System, OsseoSpeed™: Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm.
Study: NCT00846846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endeavor® Zotarolimus Eluting Coronary Stent System
Description: Endeavor® Zotarolimus Eluting Coronary Stent System in a patient population requiring stent implantation
Study: NCT03457077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief intervention
Description: A brief motivational intervention with feedback about drinking levels compared to norms

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief intervention
Description: A brief motivational intervention with feedback about drinking levels compared to norms
Study: NCT05046678

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-smokers with gingivitis
Description: without attachment and alveolar bone loss who had gingival inflammation, PD ≤ 3 mm and BOP \> 30% in the full mouth and nonsmokers if they had no previous history of smoking

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-smokers with gingivitis
Description: without attachment and alveolar bone loss who had gingival inflammation, PD ≤ 3 mm and BOP \> 30% in the full mouth and nonsmokers if they had no previous history of smoking

Intervention type: DIAGNOSTIC_TEST
Intervention: Smokers with gingivitis
Description: without attachment and alveolar bone loss who had gingival inflammation, PD ≤ 3 mm and BOP \> 30% in the full mouth and smokers if they had smoked ≥10 cigarettes/day for ≥5 years

Intervention type: DIAGNOSTIC_TEST
Intervention: Smokers with gingivitis
Description: without attachment and alveolar bone loss who had gingival inflammation, PD ≤ 3 mm and BOP \> 30% in the full mouth and smokers if they had smoked ≥10 cigarettes/day for ≥5 years
Study: NCT04595916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Isoglycyrrhizinate injection 200 mg QD
Description: Magnesium isoglycyrrhizinate injection 200mg, diluted with 5% glucose solution 250ml, once a day, at least 2 weeks but no more than 4 weeks.
Study: NCT03340753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KBP-5074 Capsule
Description: KBP-5074 (0.5 mg or 1.0 mg) capsule formulation single dose, in a 2-period crossover design with a 2-week washout/follow-up period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074 Tablet
Description: KBP-5074 (0.5 mg or 1.0 mg) tablet formulation single dose, in a 2-period crossover design with a 2-week washout/follow-up period
Study: NCT05046678

Intervention type: DIAGNOSTIC_TEST
Intervention: Smokers with gingivitis
Description: without attachment and alveolar bone loss who had gingival inflammation, PD ≤ 3 mm and BOP \> 30% in the full mouth and smokers if they had smoked ≥10 cigarettes/day for ≥5 years
Study: NCT00960830

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mirtazapine
Description: mirtazapine 15 mg daily tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mirtazapine
Description: 15 mg daily
Study: NCT02374307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and education
Description: Exercise according to the falls prevention programme. Information on motivation, the effectiveness of falls prevention and the importance of adherence.
Study: NCT00960830

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mirtazapine
Description: 15 mg daily
Study: NCT01125020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine and oxaliplatin
Description: Gemcitabine 1000mg/m2 (days l, 8) and oxaliplatin 130mg/m2 (day l) delivered as an intravenous infusion, given every 28days and repeat six times.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin, 5-Fu and cisplatin
Description: Doxorubicin 20mg/m2 (days 1, 3), 5-Fu 300mg/m2 (days 1-5) and cisplatin 20mg/m2 (days 1-3) delivered as an intravenous infusion, given every 28days and repeat six times.
Study: NCT01293760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate insertion
Description: Insertion of Copper T 380A immediately after c-section delivery of baby and placenta

Intervention type: OTHER
Group type: OTHER
Intervention: 6 weeks interval insertion
Description: Insertion of Copper T 380A 6 weeks after c-section delivery of baby and placenta
Study: NCT06052865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SENSE-plus: The Supporting and Enhancing NICU Sensory Experiences 2nd Edition (SENSE II) program
Description: The SENSE II program was developed to engage parents in consistently providing positive, developmentally appropriate sensory exposures to their high-risk infants in the NICU every day of hospitalization. The SENSE II program includes specific doses and targeted timing (based on postmenstrual age) of evidence-based interventions of auditory, tactile, vestibular, kinesthetic, olfactory, and visual exposures to be conducted daily through hospitalization for preterm infants. Additionally, for very preterm infants with advanced neurological injury, additional 1-2 sessions of weekly motor therapy are added to the SENSE-II program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SENSE: The Supporting and Enhancing NICU Sensory Experiences 2nd Edition (SENSE II) program
Description: The SENSE II program was developed to engage parents in consistently providing positive, developmentally appropriate sensory exposures to their high-risk infants in the NICU every day of hospitalization. The SENSE II program includes specific doses and targeted timing (based on postmenstrual age) of evidence-based interventions of auditory, tactile, vestibular, kinesthetic, olfactory, and visual exposures to be conducted daily through hospitalization for preterm infants.

Intervention type: OTHER
Group type: OTHER
Intervention: Reference/ Standard of care
Description: Infants in the Unexposed group receive the NICU standard of developmental care throughout hospitalization.
Study: NCT03325400

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste non-fluoride and fluoride
Description: Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm).~Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation.

Intervention type: OTHER
Group type: OTHER
Intervention: Toothpaste non-fluoride and fluoride
Description: Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm).~Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation.
Study: NCT03010813

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic single port surgery and NOTES
Description: Robotic single port colorectal surgery; Robotic transanal surgery; Robotic single port urologic surgery; Transoral robotic surgery
Study: NCT02290613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Titration:~As common practice of the clinic, the patient will adapt the dose from 5 mg to 10 mg after 1 to 4 weeks according to tolerability and after consultation (by phone or personally) with one of the investigators.~Additionally, at each study visit the investigator needs to decide, based on the patient's well-being, patients´ assessment, safety parameters, and tolerance of ambrisentan, if the study medication should be modified. The respective decision (increase, maintain or decrease dose) must be documented.~Maximum dose allowed: not to exceed 10 mg/day.~Administration:~Ambrisentan and placebo will be administered orally with or without food intake.
Study: NCT05046678

Intervention type: DIAGNOSTIC_TEST
Intervention: Smokers with periodontitis
Description: interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth and smokers if they had smoked ≥10 cigarettes/day for ≥5 years